XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.2
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Revenues $ 42,983 $ 42,692 $ 84,910 $ 74,608
Cost of products sold 31,420 32,104 61,877 56,584
Gross profit 11,563 10,588 23,033 18,024
Operating expenses:        
Research and development 1,997 1,778 3,753 3,810
Selling, general and administrative 5,649 5,145 11,300 10,523
Total operating expenses 7,646 6,923 15,053 14,333
Operating income 3,917 3,665 7,980 3,691
Interest and financing expense (418) (440) (938) (864)
Miscellaneous income 347 1,498 411 1,428
Total other (expense) income (71) 1,058 (527) 564
Income before income taxes 3,846 4,723 7,453 4,255
Income tax provision 853 1,375 1,556 1,242
Net income 2,993 3,348 5,897 3,013
Net income attributable to non-controlling interest 24 8 37 19
Net income attributable to Ultralife Corporation 2,969 3,340 5,860 2,994
Other comprehensive loss:        
Foreign currency translation adjustments (3) (293) (235) (96)
Comprehensive income attributable to Ultralife Corporation $ 2,966 $ 3,047 $ 5,625 $ 2,898
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.21 $ 0.03 $ 0.21 $ 0.21
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.21 $ 0.03 $ 0.21 $ 0.21
Weighted average shares outstanding – basic (in shares) 16,568 16,141 16,482 16,138
Potential common shares (in shares) 257 3 179 3
Weighted average shares outstanding - diluted (in shares) 16,825 16,144 16,661 16,141